BioDirecta

All Biotech companies at once!



Project information panel

3L-HeCoMe – Advanced manufacturing process to obtain a partially Bio-Resorbable Adhesive/Non-Adhesive Triple Layer Mesh for intra-peritoneal Hernia Containment

3L-HeCoMe aims to provide efficient and effective industrial solutions to innovate the production processes and products for hernia containment. Ventral hernia repairs in Europe are 400.000/year, but post-operative complications still occur, namely recurrence due to prosthetic displacement and adhesions between viscera and prosthetic surfaces. Considering estimated costs for each ventral hernia repair in Europe, costs due only to recurrence amount to 36.732.000 /year. The main aim of 3L-HeCoMe Feasibility Study(FS) is the development of an innovative process supported by enabling technologies derived from other applications and by the use of advanced materials to produce a unique medical device for the Intraperitoneal Treatment of Abdominal Wall Hernias (IPTAWH). The produced IPTAWH medical device (IPTAWH-MD) aims at preventing post-surgery problems and avoiding, or decreasing, use of mechanical surgery instruments for the mesh fixation. The IPTAWH-MD will reduce the surgical duration and costs, thanks to the following characteristics: chemical adhesive properties to parietal tissues anti-adhesion properties to viscera adequate mechanical properties, partial bioresorption. FS objectives: investigate technical development, process customization and applicability qualify 3L-HeCoMe process production output and constituting materials assess market potential and penetration routes Final users are surgeons oriented towards simplified, faster and mininvasive procedure, in the global market, which amounts to about USD 500 million and has an estimated CAGR of 7.5%, bringing to 700 million in 2019. The resulting MD will substitute actual products, giving a solid position to the SME in global markets and increasing the income, with potential sales of 259.000 452.000 /year from year 1 to 5. 3L-HeCoMe addresses societal issues avoiding hernia operation recurrence, improving quality of life of patients by reducing hospitalization and reducing healthcare

  •  01/06/2015  01/12/2015
    IT
  • H2020-EU.2.3.1.;H2020-EU.2.1.2. /  / 
  • Overall Cost: 0.07 M.Eur
  •   > Tissuemed
  • Other project partners
     
  •  
  •  
  •  
  •  



 
comments powered by Disqus


Report an error:

Did you noticed an error? Please report here...

 
  EU
 

Top Countries

 DE 933
 UK 761
 NL 663
 IT 616
 FR 516
 BE 315
 ES 306
 CH 305
 SE 237
 AT 179

Top Business Area

 RED 3029
 WHI 1096
 SEL 643
 GRE 489
 CON 311
 ANA 285
 DNA 158
 INF 144
 JOB 36

EU-Projects Champions

 Acreo 41
 Johnson 37
 DSM 32
 Biotec 30
 Tecna 28

Top Legal Types

 LTD 2380
 PLC 1071
 OTHER 89